MX2018016127A - Inhibidores de pde9 para el tratamiento de enfermedades perifericas. - Google Patents

Inhibidores de pde9 para el tratamiento de enfermedades perifericas.

Info

Publication number
MX2018016127A
MX2018016127A MX2018016127A MX2018016127A MX2018016127A MX 2018016127 A MX2018016127 A MX 2018016127A MX 2018016127 A MX2018016127 A MX 2018016127A MX 2018016127 A MX2018016127 A MX 2018016127A MX 2018016127 A MX2018016127 A MX 2018016127A
Authority
MX
Mexico
Prior art keywords
treatment
pde9 inhibitors
peripheral diseases
pde9
inhibitors
Prior art date
Application number
MX2018016127A
Other languages
English (en)
Inventor
Svenstrup Niels
I Parachikova Anna
Mcarthur James
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of MX2018016127A publication Critical patent/MX2018016127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con inhibidores PDE9, su síntesis, y su uso para el tratamiento de hiperplasia benigna de próstata, beta talasemia, y enfermedad de células falciformes.
MX2018016127A 2016-07-06 2017-06-30 Inhibidores de pde9 para el tratamiento de enfermedades perifericas. MX2018016127A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359080P 2016-07-06 2016-07-06
US201762448414P 2017-01-20 2017-01-20
PCT/US2017/040160 WO2018009424A1 (en) 2016-07-06 2017-06-30 Pde9 inhibitors for treatment of peripheral diseases

Publications (1)

Publication Number Publication Date
MX2018016127A true MX2018016127A (es) 2019-05-30

Family

ID=59363235

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018016127A MX2018016127A (es) 2016-07-06 2017-06-30 Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
MX2022010638A MX2022010638A (es) 2016-07-06 2018-12-18 Inhibidores de pde9 para el tratamiento de enfermedades perifericas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010638A MX2022010638A (es) 2016-07-06 2018-12-18 Inhibidores de pde9 para el tratamiento de enfermedades perifericas.

Country Status (10)

Country Link
US (2) US20190307754A1 (es)
EP (1) EP3481398A1 (es)
CN (2) CN114903900A (es)
AU (1) AU2017292650A1 (es)
BR (1) BR112019000005A2 (es)
CA (1) CA3025586A1 (es)
IL (2) IL295973A (es)
MX (2) MX2018016127A (es)
TN (1) TN2018000383A1 (es)
WO (1) WO2018009424A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065652T2 (hu) 2015-07-07 2024-06-28 H Lundbeck As Imidazo-pirazinon vázzal rendelkezõ PED9 inhibitor perifériális betegségek kezelésére
ES2975792T3 (es) 2018-05-25 2024-07-15 Cardurion Pharmaceuticals Inc Monohidrato y formas cristalinas de 6-[(3s,4s)-4-metil-1- (pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7H-imidazo[1,5-a]pirazin-8-ona
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
WO2020043033A2 (zh) * 2018-08-31 2020-03-05 苏州鹏旭医药科技有限公司 一种乌帕替尼及其中间体的合成方法
AU2019328299A1 (en) * 2018-08-31 2021-04-22 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease
US20210386743A1 (en) * 2018-10-08 2021-12-16 The Johns Hopkins University Use of pde9 inhibitors for treatment
JP2022527630A (ja) * 2019-04-05 2022-06-02 イマラ インク． 鎌状赤血球症を治療するためのｐｄｅ９阻害剤
WO2020227399A1 (en) * 2019-05-07 2020-11-12 Imara Inc. Pde9 inhibitors for treating thalassemia
JP2023510111A (ja) * 2019-12-19 2023-03-13 クリア、スペイン、エセ、ア、ウ ウパダシチニブの調製のための方法及び中間体
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
IL302423A (en) * 2020-10-27 2023-06-01 Cardurion Pharmaceuticals Inc PDE9 inhibitors for the treatment of heart failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0774963T3 (da) 1994-08-08 2001-01-29 Debiopharm Sa Farmaceutisk stabilt oxaliplatin-præparat
EP1368022B1 (fr) 2001-03-02 2007-06-20 Debiopharm S.A. Utilisation d'un flacon contenant une solution d'oxaliplatine
WO2004037311A2 (en) 2002-10-21 2004-05-06 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
KR101222330B1 (ko) 2007-05-11 2013-01-15 화이자 인코포레이티드 아미노-헤테로시클릭 화합물
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
EP2906562B1 (en) 2011-10-10 2016-10-05 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
AU2013308464B2 (en) 2012-08-31 2018-02-01 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
JP6431528B2 (ja) 2013-04-10 2018-11-28 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 癌治療のための薬物局所送達装置及び方法
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015185499A1 (en) * 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
HUE065652T2 (hu) * 2015-07-07 2024-06-28 H Lundbeck As Imidazo-pirazinon vázzal rendelkezõ PED9 inhibitor perifériális betegségek kezelésére

Also Published As

Publication number Publication date
US20210085684A1 (en) 2021-03-25
IL295973A (en) 2022-10-01
US20190307754A1 (en) 2019-10-10
MX2022010638A (es) 2022-09-23
BR112019000005A2 (pt) 2019-04-16
TN2018000383A1 (en) 2020-06-15
EP3481398A1 (en) 2019-05-15
CN114903900A (zh) 2022-08-16
AU2017292650A1 (en) 2018-12-13
CA3025586A1 (en) 2018-01-11
CN109475556A (zh) 2019-03-15
WO2018009424A1 (en) 2018-01-11
IL264048A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
TN2017000507A1 (en) Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
MY186311A (en) Bicyclic heterocycle compounds and their uses in therapy
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
PH12015502161A1 (en) Therapeutic compounds and compositions
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX364859B (es) Derivados de imidazopirazinona.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX369393B (es) Derivados de ftalazina.
PH12020500472A1 (en) Autotaxin inhibitor compounds
MA44025A1 (fr) Inhibiteurs de pde9 pour le traitement de maladies périphériques
UA112552C2 (uk) Гетероцикліламіни як інгібітори pi3k
EA201991791A3 (ru) Гетероциклиламины как ингибиторы pi3k